Welcome to CanCan Diagnostics
CanCan Diagnostics is a veterinary diagnostics company developing advanced blood tests for the detection and monitoring of cancer in dogs and cats.
Its core technology uses next generation sequencing to identify cancer related mutations in cell free DNA circulating in the bloodstream.
Its flagship K9 LiquiDx™ liquid biopsy is designed to support cancer screening, early diagnosis, disease monitoring and earlier detection of relapse in dogs. CanCan is working on a groundbreaking tissue and liquid biopsy for cats to be released Q1 2027.
The technology requires only a routine blood draw, providing veterinarians with a minimally invasive alternative or complement to traditional diagnostic approaches. CanCan sends you a kit, you do the blood draw and return the kit to us by UPS. Simple.
By combining genomic sequencing with veterinary oncology expertise, CanCan aims to improve the precision, speed and quality of cancer care for companion animals.
Cancer is one of the leading causes of death in dogs, with between 30-50% of animals developing it in their lifetime. It is estimated that 1 in 4 dogs will develop cancer in their lifetime. The estimated number of cats developing cancer is estimated to be 1 in 3
CanCan Diagnostics was founded in 2022 by Dr. Maciej Parys as a spin out from the University of Edinburgh. It won the “Innovation: Animal Health, Agritech, and Aquaculture” award at the 2026 Scotland’s Life Sciences Awards.
Explore the CANCAN Diagnostics Blog – Your Gateway to Pet Cancer Care Insights. Stay updated with the latest industry news, business highlights, and expert tips on revolutionizing pet healthcare through liquid biopsy.
